Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
3.100
-0.050 (-1.59%)
Jul 22, 2025, 10:26 AM - Market open
BDTX Employees
Black Diamond Therapeutics had 24 employees as of December 31, 2024. The number of employees decreased by 30 or -55.56% compared to the previous year.
Employees
24
Change (1Y)
-30
Growth (1Y)
-55.56%
Revenue / Employee
$2,916,667
Profits / Employee
$212,125
Market Cap
176.27M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BDTX News
- 6 weeks ago - Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside - Seeking Alpha
- 7 weeks ago - Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha
- 4 months ago - Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy - GlobeNewsWire
- 4 months ago - Black Diamond Therapeutics: In Decline, But Why? - Seeking Alpha
- 4 months ago - Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire